Comment on: “Efficacy and Safety of Saroglitazar in Patients with Cardiometabolic Diseases: A Systematic Review and Meta-Analysis of Randomized Controlled Trials”-Reference-Cited by-同舟云学术

Comment on: “Efficacy and Safety of Saroglitazar in Patients with Cardiometabolic Diseases: A Systematic Review and Meta-Analysis of Randomized Controlled Trials”

Published:2023-01-13 Issue:2 Volume:43 Page:147-148
ISSN:1173-2563
Container-title:Clinical Drug Investigation
language:en
Short-container-title:Clin Drug Investig

Author:

Dutta Deep^ORCID,Mohindra Ritin,Misra Anoop

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s40261-022-01245-4.pdf

Reference8 articles.

1. Durga DR, Mounika N, Mudimala P, Adela R. Efficacy and safety of saroglitazar in patients with cardiometabolic diseases: a systematic review and meta-analysis of randomized controlled trials. Clin Drug Investig. 2022. https://doi.org/10.1007/s40261-022-01219-6.

2. Chhabra M, Vidyasagar K, Gudi SK, Sharma J, Sharma R, Rashid M. Efficacy and safety of saroglitazar for the management of dyslipidemia: a systematic review and meta-analysis of interventional studies. PLoS ONE. 2022;17:e0269531. https://doi.org/10.1371/journal.pone.0269531.

3. Dutta D, Bhattacharya S, Surana V, Aggarwal S, Singla R, Khandelwal D, Sharma M. Efficacy and safety of saroglitazar in managing hypertriglyceridemia in type-2 diabetes: a meta-analysis. Diabetes Metab Syndr. 2020;14:1759–68.

4. Pai V, Paneerselvam A, Mukhopadhyay S, Bhansali A, Kamath D, Shankar V, et al. A multicenter, prospective, randomized, double-blind study to evaluate the safety and efficacy of saroglitazar 2 and 4 mg compared to pioglitazone 45 mg in diabetic dyslipidemia (PRESS V). J Diabetes Sci Technol. 2014;8:132–41.

5. Jani RH, Pai V, Jha P, Jariwala G, Mukhopadhyay S, Bhansali A, et al. A multicenter, prospective, randomized, double-blind study to evaluate the safety and efficacy of saroglitazar 2 and 4 mg compared with control in type 2 diabetes mellitus patients having hypertriglyceridemia not controlled with atorvastatin therapy (PRESS VI). Diabetes Technol Ther. 2014;16:63–71.

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Response to Comment on: “Efficacy and Safety of Saroglitazar in Patients with Cardiometabolic Diseases: A Systematic Review and Meta-Analysis of Randomized Controlled Trials”;Clinical Drug Investigation;2023-01-12